Top Back to top

Efficacy and Toxicity of ponatinib and 2nd generation TKI given after allogeneic SCT in Ph+ adult ALL.

Acute Leukemia Working Party (ALWP)
Study type:
Study number:
84210101
Type of Stem Cell Treatment:
Allogeneic
Diseases:
Acute Lymphatic Leukaemia (ALL)
Short title:
TKI 2nd/mrd generation in Ph+ ALL
Primary objective:
 
Key inclusion criteria:
 
Country:
 
Principal investigator:
Klaus HIRSCHBUEHL
EBMT Study coordinator:
Mohamed HOUHOU
Study coordinator email:
mohamed.houhou@upmc.fr